loading page

Interleukin-35 Play Tumor Promoting Roles in Hepatocellular Carcinoma
  • +2
  • na zhao,
  • Xin Liu,
  • Hao Guo,
  • He Ren,
  • Wei Wang
na zhao
Tianjin Medical University General Hospital
Author Profile
Xin Liu
Tianjin Medical University General Hospital
Author Profile
Hao Guo
Tianjin Medical University General Hospital
Author Profile
He Ren
Tianjin Medical University General Hospital
Author Profile
Wei Wang
Tianjin Medical University General Hospital
Author Profile

Abstract

Backgroud: A long-term hepatic inflammatory response is a risk factor for liver cancer initiation and progression. Interleukin (IL)-35 is the newest member of the IL-12 cytokine family, and has been reported to play an essential role in the immunosuppressive liver microenvironment. Herein we focus on the expression profiles of IL-35 in hepatocellular carcinoma (HCC) and the effect on local immune status. Methods: HCC transcriptome array data were downloaded from Gene Expression Omnibus. The bioinformatics analysis was performed by the BRB array tools and online Ingenuity Pathway Analysis software. The serum IL-35 level was detected by AimPlet bead-based immunoassay. In situ IL-35 expression detection was performed by immunohistochemical staining and western blot. Results: Our results showed that there were large amounts of IL-35 expressed in HCC serum and tumor tissues. IL-35 expression affects the transcript of thousands of genes, most of which correlated with T-cell immunity. This study proved that enhancement of regulatory T cells (Tregs) and impairment of cytolytic T cells are prominent effects of IL-35. Conclusions: Elevated IL-35 played critical roles in HCC patients through affecting the balance between Tregs and cytotoxic T cells. Dissection of the precise targets and the underlying molecular mechanisms will lead to alternative treatments for HCC patients.

Peer review status:ACCEPTED

21 Feb 2020Submitted to Clinical & Experimental Immunology
21 Feb 2020Submission Checks Completed
21 Feb 2020Assigned to Editor
27 Feb 2020Reviewer(s) Assigned
24 Mar 2020Review(s) Completed, Editorial Evaluation Pending
24 Mar 2020Editorial Decision: Revise Major
04 Jul 20201st Revision Received
07 Jul 2020Reviewer(s) Assigned
30 Jul 2020Review(s) Completed, Editorial Evaluation Pending
13 Aug 2020Editorial Decision: Revise Minor
20 Aug 20202nd Revision Received
21 Aug 2020Review(s) Completed, Editorial Evaluation Pending
18 Sep 2020Editorial Decision: Accept